Dr. Charles Simone II, MD

• Radiation Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• National Cancer Institute, Nih

  Residency Hospital

• National Cancer Institute-nih

  Internship Hospital

• University Of Pennsylvania Perelman School Of Medicine

  Medical School

• University Of Pennsylvania (upenn)

  Undergraduate School

• Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab, 2021-12-20

• The Utilization of Oncology Web-based Resources in Spanish-speaking Internet Users, 2011-05-04

• A PILOT AND FEASIBILITY CLINICAL TRIAL EVALUATING IMMUNO-GENE THERAPY OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) USING INTRAPLEURAL DELIVERY OF ADENOVIRUS- INTERFERON-ALPHA (Ad.hIFN-a2b) IN COMBINATION WITH HIGH-DOSE CELECOXIB AND SYSTEMIC CHEMOTHERAPY, 2016-03-11

• Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab Outcomes in Patients with Locally Advanced NSCLC Treated With Chemoradiation and Durvalumab, 2023-01-05

• Using Machine Learning to Predict Radiation Pneumonitis in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy, 2016-07-27

• Whole Pelvic Intensity-modulated Radiotherapy for Gynecological Malignancies: A Review of the Literature, 2015-01-03

• Fractionated Radiation Alters Oncomir and Tumor Suppressor miRNAs in Human Prostate Cancer Cells, 2012-07-24

• A Preclinical Model to Investigate the Role of Surgically-Induced Inflammation in Tumor Responses to Intraoperative Photodynamic Therapy, 2018-05-25

• Real-time treatment feedback guidance of Pleural PDT, 2013-02-02

• The Impact of Durvalumab on Local Regional Control in Stage III Non-Small Cell Lung Cancers Treated with Chemoradiation and on KEAP1/NFE2L2 Mutant Tumors, 2021-05-13

• Editorial: Combining multiple non-invasive images and/or biochemical tests to predict prostate cancer aggressiveness, 2023-02-14

• Proton Therapy in the Management of Luminal Gastrointestinal Cancers: Esophagus, Stomach, and Anorectum, 2022-06-10

• Proton Therapy in the Management of Hepatocellular Carcinoma, 2022-06-12

• Proton Therapy for Partial Breast Irradiation: Rationale and Considerations, 2021-04-09

• Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab, 2020-04-30

• CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors, 2021-04-09

• Assessing and testing anomaly detection for finding prostate cancer in spatially registered multi-parametric MRI, 2023-01-05

• Proton Therapy in the Management of Pancreatic Cancer, 2022-06-04

• ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy, 2023-09-19

• Comparing proton treatment plans of pediatric brain tumors in two pencil beam scanning nozzles with different spot sizes, 2015-11-08

• Intensity-Modulated Proton Therapy for Elective Nodal Irradiation and Involved-Field Radiation in the Definitive Treatment of Locally Advanced Non-Small Cell Lung Cancer: A Dosimetric Study, 2014-12-09

• Cancer Patient Attitudes Towards Analgesic Utilization and Pain Intervention, 2011-06-15

• Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab, 2020-05-06

• Particle Therapy for Non-Small Cell Lung Tumors: Where Do We Stand? A Systematic Review of the Literature, 2014-10-29

• Racial inequity and other social disparities in the diagnosis and management of bladder cancer, 2022-06-08

• Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC, 2016-05-04

• Brief Report: A Survey of Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group, 2016-11-19

• Integration of Deep Learning Radiomics and Counts of Circulating Tumor Cells Improves Prediction of Outcomes of Early Stage NSCLC Patients Treated With Stereotactic Body Radiation Therapy, 2021-11-11

• Dynamic simulation of motion effects in IMAT lung SBRT, 2014-11-01

• Treatment planning and outcomes effects of reducing the preferred mean esophagus dose for conventionally fractionated non-small cell lung cancer radiotherapy YORKEet al., 2021-01-25

• Light dosimetry and dose verification for pleural PDT, 2013-02-02

• Real-time treatment light dose guidance of Pleural PDT: an update, 2015-03-02

• MediBoost: a Patient Stratification Tool for Interpretable Decision Making in the Era of Precision Medicine, 2016-11-30

• Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Undergoing Post-Operative Radiation Therapy, 2020-10-14

• Lesion Oxygenation Associates with Clinical Outcomes in Premalignant and Early Stage Head and Neck Tumors Treated on a Phase 1 Trial of Photodynamic Therapy, 2017-11-04

• Integration of risk survival measures estimated from pre- and post-treatment CT scans improves stratification of early stage non-small cell lung cancer patients treated with stereotactic body radiation therapy, 2021-01-19

• Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer, 2022-02-12